Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AP707 for chronic traumatic or post-operative peripheral neuropathic pain
2022-500898-13-00Phase 3Completed
- Sponsor
- Cannaxan
- Start
- Nov 2023
- Modality
- Small Molecules, Lipid-mediated Delivery → Gene Addition/Replacement → Gene Therapies, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in peripheral neuropathy and Neuralgia comparing AP707 with Placebo (2 arms). Primary endpoint: Change in Numeric Rating Scale pain score at week 14. Started Nov 2023; status: completed.
02
Drugs
adezunap
03
Conditions
peripheral neuropathyNeuralgia
Beyond the preview
Go deeper on 2022-500898-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500898-13-00.